Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1478221 | 0.97 | MAPK1 (0.34) | MAPK1 | |
| SCHEMBL6427566 | 0.93 | — | — | |
| SCHEMBL11053976 | 0.86 | — | — | |
| SCHEMBL4515851 | 0.73 | ADRB1 (0.36) | — | |
| SCHEMBL30201385 | 0.69 | — | — | |
| SCHEMBL3918550 | 0.67 | — | — | |
| SCHEMBL78337 | 0.64 | MGLL (0.33) | — | |
| SCHEMBL515359 | 0.64 | MGLL (0.33) | — | |
| SCHEMBL102770 | 0.64 | POLB (0.33) | — | |
| SCHEMBL540364 | 0.64 | NFKB1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9865823-B2 | Quinolinium dyes with fluorinated counter anion for dye sensitized solar cells | BASF SE (DE) | 2018-01-09 | — | — | US | claimed |
| US-20150108415-A1 | QUINOLINIUM DYES WITH FLUORINATED COUNTER ANION FOR DYE SENSITIZED SOLAR CELLS | BASF SE (DE) | 2015-04-23 | — | — | US | claimed |
| EP-2831180-A1 | QUINOLINIUM DYES WITH FLUORINATED COUNTER ANION FOR DYE SENSITIZED SOLAR CELLS | BASF SE (DE) | 2015-02-04 | — | — | EP | claimed |
| US-8933096-B2 | Antimicrobial agents | Rugers, The State University of New Jersey (US) | 2015-01-13 | — | — | US | claimed |
| WO-2013144177-A1 | QUINOLINIUM DYES WITH FLUORINATED COUNTER ANION FOR DYE SENSITIZED SOLAR CELLS | BASF SE (DE) | 2013-10-03 | — | — | WO | claimed |
| US-20130116278-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2013-05-09 | — | — | US | claimed |
| US-20130109713-A1 | ANTIMICROBIAL AGENTS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2013-05-02 | — | — | US | claimed |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | claimed |
| WO-2011163610-A2 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-12-29 | — | — | WO | claimed |
| WO-2011156626-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-12-15 | — | — | WO | claimed |
| EP-0751944-B1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2000-12-20 | — | — | EP | claimed |
| WO-2000059836-A1 | USE OF AN ACRYLIC POLYMER OR FUNCTIONALIZED SILICA SUPPORT IN SUPPORTED CATALYSIS | SOCIETE D'EXPANSION SCIENTIFIQUE EXPANSIA (FR) | 2000-10-12 | — | — | WO | claimed |
| US-6117865-A | FOR CONTROLLING FUNGUS IN PLANTS | AMERICAN CYANAMID COMPANY (US) | 2000-09-12 | — | — | US | claimed |
| US-5958903-A | CHOLINESTERASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1999-09-28 | — | — | US | claimed |
| US-5773444-A | Quinazolines as inhibitors of endothelin converting enzyme | WARNER-LAMBERT COMPANY (US) | 1998-06-30 | — | — | US | claimed |
| EP-0839149-A1 | GALANTHAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, USE THEREOF AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH DERIVATIVES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1998-05-06 | — | — | EP | claimed |
| EP-0821585-A1 | USE OF $g(a) 1L? AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1998-02-04 | — | — | EP | claimed |
| US-5658902-A | HYPOTENSIVE AGENTS; ANTIISCHEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| WO-1997003987-A1 | NOVEL GALANTHAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, USE THEREOF AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH DERIVATIVES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1997-02-06 | — | — | WO | claimed |
| WO-1996032939-A1 | USE OF α1L AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1996-10-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116278-A1 | ANTIMICROBIAL AGENTS | MRPL21, ARG1, RPP30 | MAPK1 1907/4885 |
| US-20130109713-A1 | ANTIMICROBIAL AGENTS | RPS4X, RPS4Y1, MRPL21 | MAPK1 1591/4885 |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | MAPK1 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.